Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

  1. Rugo, H.S.
  2. Dieras, V.
  3. Cortes, J.
  4. Patt, D.
  5. Wildiers, H.
  6. O’Shaughnessy, J.
  7. Zamora, E.
  8. Yardley, D.A.
  9. Carter, G.C.
  10. Sheffield, K.M.
  11. Li, L.
  12. Andre, V.A.M.
  13. Li, X.I.
  14. Frenzel, M.
  15. Huang, Y.-J.
  16. Dickler, M.N.
  17. Tolaney, S.M.
Revue:
Breast Cancer Research and Treatment

ISSN: 1573-7217,  0167-6806

Année de publication: 2020

Volumen: 184

Número: 1

Pages: 161-172

Type: Article

DOI: 10.1007/S10549-020-05838-5 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus